Low dose intravenous cangrelor versus glycoprotein IIb/IIIa inhibitors in endovascular treatment of tandem lesions
Jumaa M, Rodriguez-Calienes A, Dawod G, Vivanco-Suarez J, Hassan A, Divani A, Oliver M, Ribo M, Petersen N, Abraham M, Fifi J, Guerrero W, Malik A, Siegler J, Nguyen T, Sheth S, Yoo A, Linares G, Janjua N, Quispe-Orozco D, Galecio-Castillo M, Zevallos C, Malaga M, Farooqui M, Jovin T, Zaidi S, Ortega-Gutierrez S. Low dose intravenous cangrelor versus glycoprotein IIb/IIIa inhibitors in endovascular treatment of tandem lesions. Journal Of Stroke And Cerebrovascular Diseases 2023, 32: 107438. PMID: 37883826, PMCID: PMC11271813, DOI: 10.1016/j.jstrokecerebrovasdis.2023.107438.Peer-Reviewed Original ResearchConceptsSymptomatic intracranial hemorrhageGP IIb/IIIa inhibitorsRate of symptomatic intracranial hemorrhageGP IIb/IIIaAntiplatelet therapyMechanical thrombectomyRetrospective non-randomized cohort studyGP IIb/IIIa inhibitor groupHemorrhagic infarction type 1Tandem lesionsComplete reperfusionType 1Periprocedural antiplatelet therapyReducing hemorrhage ratesParenchymal hematoma type 1Treatment of tandem lesionsNon-randomized cohort studyAcute carotid stentingIntravenous (IVGlycoprotein IIb/IIIa inhibitorsRate of complete reperfusionAssociated with increased oddsCangrelor groupHemorrhage rateIntravenous cangrelor